Blood Res 2020; 55(1):
Published online March 31, 2020
https://doi.org/10.5045/br.2020.55.1.67
© The Korean Society of Hematology
Correspondence to : Stephen E. Langabeer
Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James’s Hospital, Dublin D08 W9RT, Ireland
E-mail: slangabeer@stjames.ie
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In a recent issue of
This important finding raises some considerations. In addition to improved communication between hematologists and neurologists, would the authors suggest implementation and justification of an MPN-associated molecular screening programme for all patients with stroke, regardless of the presence of an erythrocytosis or thrombocytosis? Furthermore, the vast majority of MPN patients presenting with stroke have molecular evidence of the
No potential conflicts of interest relevant to this article were reported.
Blood Res 2020; 55(1): 67-68
Published online March 31, 2020 https://doi.org/10.5045/br.2020.55.1.67
Copyright © The Korean Society of Hematology.
Stephen E. Langabeer
Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland
Correspondence to:Stephen E. Langabeer
Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James’s Hospital, Dublin D08 W9RT, Ireland
E-mail: slangabeer@stjames.ie
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In a recent issue of
This important finding raises some considerations. In addition to improved communication between hematologists and neurologists, would the authors suggest implementation and justification of an MPN-associated molecular screening programme for all patients with stroke, regardless of the presence of an erythrocytosis or thrombocytosis? Furthermore, the vast majority of MPN patients presenting with stroke have molecular evidence of the
No potential conflicts of interest relevant to this article were reported.